| 英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
|---|---|---|---|---|---|---|
|
AZD8931
|
848942-61-0 |
AZD8931
|
CS-368;AZD-8931;AZD8931;AZD 8931;AZD8931 (SAPITINIB);AZD 8931;4-(3-氯-2-氟苯胺基)-7-甲氧基-6-[[1-(N-甲基氨基甲酰甲基)哌啶-4-基]氧基]喹唑啉;2-(4-(4-(3-氯-2-氟苯基氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-N-甲基乙酰胺;沙普替尼
|
C23H25ClFN5O3 |
473.927703 | |
|
LY2886721
|
1262036-50-9 |
N-[3-[(4AS,7AS)-2-氨基-4A,5-二氢-4H-呋喃并[3,4-D][1,3]噻嗪-7A(7H)-基]-4-氟苯基]-5-氟-2-吡啶甲酰胺
|
N-[3-[(4AS,7AS)-2-氨基-4A,5-二氢-4H-呋喃并[3,4-D][1,3]噻嗪-7A(7H)-基]-4-氟苯基]-5-氟-2-吡啶甲酰胺;LY 2886721盐酸
|
C18H16F2N4O2S |
390.41 | |
|
PD 0332991 Hydrochloride
|
827022-32-2 |
PD332991
|
盐酸帕布昔利布;帕布昔利布标准品025;PALBOCICLIB;PD-0332991 HYDROCHLORIDE;PD0332991 HYDROCHLORIDE;PD 0332991 HYDROCHLORIDE;帕布昔利布盐酸盐;帕博西林盐酸盐;帕博西尼盐酸盐,一种高度选择性的CDK4;6抑制剂;CS-365;PD 0332991;PD-0332991
|
C24H30ClN7O2 |
483.9937 | 1592732-453-0 |
|
VX-702
|
479543-46-9 |
6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺
|
CS-363
|
C19H12F4N4O2 |
404.322 | |
|
Brivanib alaninate
|
649735-63-7 |
1-[[4-[(4-氟-2-甲基-1H-吲哚-5-基)氧基]-5-甲基吡咯并[2,1-F][1,2,4]三嗪-6-基]氧基]-2-丙醇 L-丙氨酸酯
|
BMS-582664;BMS 582664;BMS582664;L-丙氨酸(1R)-2-[[4-[(4-氟-2-甲基-1H-吲哚-5-氧基)]-5-甲基-1H-吡咯并[2,1-F][1,2,4]三嗪-6-基]氧基]异丙基酯;丙氨酸布立尼布;布立尼布丙氨酸酯;1-[[4-[(4-氟-2-甲基-1H-吲哚-5-基)氧基]-5-甲基吡咯并[2,4]三嗪-6-基]氧基]-3-丙醇 L-丙氨酸酯;BRIVANIB 丙氨酸酯;丙氨酸酯
|
C19H18FN4O3 |
369.369623 | |
|
BMS-777607
|
1025720-94-8 |
N-[4-[(2-氨基-3-氯吡啶-4-基)氧基]-3-氟苯基]-4-乙氧基-1-(4-氟苯基)-2-氧代-1,2-二氢吡啶-3-甲酰胺
|
N-[4-[(2-氨基-3-氯吡啶-4-基)氧基]-3-氟苯基]-4-乙氧基-1-(4-氟苯基)-2-氧代-1,2-二氢吡啶-3-甲酰胺;N-[4-[(2-氨基-3-氯-4-吡啶)氧基]-3-氟苯基]-4-乙氧基-1-(4-氟苯基)-1,2-二氢-2-氧代-3-吡啶羧酰胺
|
C25H19ClF2N4O4 |
512.8925664 | |
|
enzalutamide
|
915087-33-1 |
恩杂鲁胺(Enzalutamide)
|
恩扎鲁胺;4-[3-[4-氰基-3-(三氟甲基)苯基]-5,5-二甲基-4-氧代-2-硫酮-1-咪唑烷基]-2-氟-N-甲基苯甲酰胺 (恩扎鲁胺);4-(3-(4-氰基-3-(三氟甲基)苯基)-5,5-二甲基-4-氧代-2-硫代咪唑啉-1-基)-2-氟-N-甲基苯甲酰胺;恩杂鲁胺(MDV3100);4-[3-[4-氰基-3-(三氟甲基)苯基]-5,5-二甲基-4-氧代-2-硫代-1-咪唑烷基]-2-氟-N-甲基苯甲酰胺;MDV3100,恩杂鲁胺
|
C21H16F4N4O2S |
464.4359528 | |
|
boceprevir
|
394730-60-0 |
波普瑞韦
|
EBP 520;SCH 503034;EBP-520;EBP520;SCH-503034;SCH503034);CS-355;波西普韦杂质;伯克匹韦;波普瑞韦及中间体;波西;波西普韦;波普瑞韦(博塞匹韦)
|
C27H45N5O5 |
519.6767 | 800-043-2 |
|
Solifenacin succinate
|
242478-38-2 |
索非那新琥珀酸盐
|
琥珀酸索非那新;索利那新-索非那新杂质;1-氮杂双环[2.2.2]辛烷-8-基-(1S)-1-苯基-3,4-二氢-1H-异喹啉-3-甲酸酯丁二酸盐;索非那新琥珀酸盐;琥珀酸素立芬新;琥珀酸索非那新;琥铂酸索非那新;索非那新琥珀酸
|
C23H26N2O2. C4H6O4;C27H32N2O6 |
480.56 | 620-505-5 |
|
ibudilast
|
50847-11-5 |
异丁司特
|
2-甲基-1-[2-(1-甲基乙基)吡唑啉[1,5-a]吡啶-3-基]-1-丙酮;异丁司特 1G;异丁司特;3-异丁酰-2-异丙基吡唑并[1,5-Α]吡啶;依布拉特;2-甲基-1-[2-(1-甲基乙基)吡唑并[1,5-A]吡啶-3-基]-2-丙酮;依布司特
|
C14H18N2O |
230.31 | 637-150-7 |
|
QS 11
|
944328-88-5 |
QS11
|
QS11;(2S)-2-[2-(Indan-5-yloxy)-9-(1,1'-biphenyl-4-yl)methyl)-9H-purin-6-ylamino]-3-phenyl-propan-1-ol;(betaS)-beta-[[9-([1,1'-Biphenyl]-4-ylmethyl)-2-[(2,3-dihydro-1H-inden-5-yl)oxy]-9H-purin-6-yl]amino]benzenepropanol;QS 11
(betaS)-beta-[[9-([1,1'-Biphenyl]-4-ylmethyl)-2-[(2,3-dihydro-1H-inden-5-yl)oxy]-9H-purin-6-yl]amino]benzenepropanol;(2S)-2-[2-(Indan-5-yloxy)-9-(1,1′-biphenyl-4-yl)methyl)-9H-purin-6-ylamino]-3-phenyl-propan-1-ol hydrate;QS11 hydrate;(S)-2-((9-([1,1'-Biphenyl]-4-ylmethyl)-2-((2,3-dihydro-1H-inden-5-yl)oxy)-9H-purin-6-yl)amino)-3-phenylpropan-1-ol;Wnt Synergist, QS11 - CAS 944328-88-5 - Calbiochem
|
C36H33N5O2 |
||
|
SNX-2112
|
908112-43-6 |
SNX-2112;4-(6,6-DIMETHYL-4-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-INDAZOL-1-YL)-2-((1R,4R)-4-HYDROXYCYCLOHEXYLAMINO)BENZAMIDE
|
|
C23H27F3N4O3 |
464 | |
|
Tofacitinib
|
477600-75-2 |
托法替尼
|
托法替布(托法替尼);3-((3R,4R)-4-甲基-3-(甲基(7H-吡咯并[2,3-D]嘧啶-4-基)氨基)哌啶-1-基)-3-氧代丙腈;(3R,4R)-4-甲基-3-(甲基-7H-吡咯并[2,3-D]嘧啶-4-基氨基)-BETA-氧代-1-哌啶丙腈;3-((3R,3-D]嘧啶-4-基)氨基)哌啶-1-;1-哌啶丙腈,4-甲基-3-(甲基-7H-吡咯并[2,3-D]嘧啶-4-基氨基)-Β-氧代-,(3R,4R)-;他索替尼;CP690550<3-<<3R,4R>-4-甲基-3-<甲基<7H-吡咯并<2,3-D>嘧啶-4-基>氨基>哌啶-1-基>-3-氧代丙腈>;托法替尼
|
C16H20N6O |
312.37 | 689-145-4 |
|
Apixaban
|
503612-47-3 |
阿哌沙班
|
阿匹沙班;4,5,6,7-四氢-1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代-1-哌啶基)苯基]-1H-唑唑并[3,4-C]吡啶-3-羰胺;4,7-四氢-1-(4-甲氧基苯基)-7-氧代-6-[4-(2-氧代-1-哌啶基)苯基]-1H-吡唑并[3,4-C]吡啶-3-甲酰胺;BMS562247;阿哌沙班;阿;阿哌沙班API;阿哌沙班对照品
|
C25H25N5O4 |
459.5 | 639-684-6 |
|
imipenem hydrate
|
74431-23-5 |
亚胺培南(一水物)
|
伊米配能;亚胺硫霉素一水合物;5-(2-氯苯甲基)-4,5,6,7-四氢噻吩并[3,2-C]吡啶盐酸盐;亚胺培南一水合物;亚胺培南水合物;亚胺培南(标准品);IMIPENEM 亚胺培南;亚胺培南杂质对照品
|
C12H17N3O4S.H2O |
317.36 | 680-398-6 |
|
Sitaxsentan sodium (TBC-11251)
|
210421-74-2 |
Sitaxentan sodium
|
(4-氯-3-甲基-1,2-恶唑-5-基)-[2-[2-(6-甲基-1,3-苯并二氧戊环-5-基)乙酰基]噻吩-3-基]磺酰亚胺钠盐;司他生坦钠;西他塞坦钠;司他生坦钠;CS-338;西他塞坦钠;心脑血管类原料药;西他生坦钠;CS-777
|
C18H14ClN2NaO6S2 |
476.89 | 606-692-6 |
|
PD184352 (CI-1040)
|
212631-79-3 |
2-[(2-氯-4-碘苯基)氨基]-N-(环丙基甲氧基)-3,4-二氟-苯甲酰胺
|
CS-333;2-(2-氯-4-碘苯氨基)-N-(环丙基甲氧基)-3,4-二氟苯酰胺;2-[(2-氯-4-碘苯基)氨基]-N-(环丙基甲氧基)-3,4-二氟-苯甲酰胺;PD 184352;CI-1040;PD-184352;2-[(2-氯-4-碘苯基)胺]-N-(环丙基甲氧基)-3,4-二氟苯甲胺;-[(2-氯-4-碘苯基)氨基]-N-(环丙基甲氧基)-3,4-二氟-苯甲酰胺;CI1040;PD-184352;CI 1040 (PD184352);2-(2-氯-4-碘苯氨基)-N-(环丙基甲氧基)-3,4-二氟苯甲酰胺
|
C17H14ClF2IN2O2 |
478.659536 | |
|
retapamulin
|
224452-66-8 |
瑞他莫林
|
瑞他莫林;瑞他帕林;瑞他莫林;瑞他帕林;CS-330;瑞他怕林;瑞他帕林.瑞他莫林;瑞他莫林(成熟)
|
C30H47NO4S |
517.77 | 639-491-7 |
|
Nepafenac
|
78281-72-8 |
奈帕芬胺
|
2-(2-氨基-3-苯甲酰苯基)乙酰胺;奈帕芬胺(标准品);2-氨基-3-苯甲酰基苯乙酰胺;奈帕芬胺;奈帕酚胺;奈帕酚胺,一种选择性COX-2 抑制剂;奈帕芬酸杂质
|
C15H14N2O2 |
254.28 | |
|
lurasidone
|
367514-87-2 |
鲁拉西酮
|
鲁拉西酮;卢拉西酮;鲁拉西酮LURASIDONE;盐酸鲁拉西酮API;鲁拉西酮(仅供中间体);SM13496;SM-13496;SM 13497
|
C28H36N4O2S |
492.68 | 696-042-8 |







